Department of Pharmaceutical and Pharmacological Sciences, University of Padova, 35131 Padova, Italy.
Division of Cardiology, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, 80131 Napoli, Italy.
Int J Mol Sci. 2021 Feb 19;22(4):2049. doi: 10.3390/ijms22042049.
Resistance to chemotherapy still remains a major challenge in the clinic, impairing the quality of life and survival rate of patients. The identification of unconventional chemosensitizing agents is therefore an interesting aspect of cancer research. Resveratrol has emerged in the last decades as a fascinating molecule, able to modulate several cancer-related molecular mechanisms, suggesting a possible application as an adjuvant in cancer management. This review goes deep into the existing literature concerning the possible chemosensitizing effect of resveratrol associated with the most conventional chemotherapeutic drugs. Despite the promising effects observed in different cancer types in in vitro studies, the clinical translation still presents strong limitations due to the low bioavailability of resveratrol. Recently, efforts have been moved in the field of drug delivery to identifying possible strategies/formulations useful for a more effective administration. Despite the necessity of a huge implementation in this research area, resveratrol appears as a promising molecule able to sensitize resistant tumors to drugs, suggesting its potential use in therapy-refractory cancer patients.
化疗耐药仍然是临床治疗的主要挑战，降低了患者的生活质量和生存率。因此，寻找非传统的化疗增敏剂是癌症研究的一个有趣方面。白藜芦醇在过去几十年中作为一种引人注目的分子出现，能够调节几种与癌症相关的分子机制，提示其可能作为癌症治疗的辅助剂应用。本文深入探讨了白藜芦醇与最常用的化疗药物联合应用的可能化疗增敏作用的现有文献。尽管在不同类型的癌症的体外研究中观察到了有希望的效果，但由于白藜芦醇的生物利用度低，其临床转化仍然存在很大的局限性。最近，人们在药物输送领域做出了努力，以寻找可能有助于更有效给药的策略/配方。尽管在这一研究领域需要大量的投入，但白藜芦醇似乎是一种有前途的分子，能够使耐药肿瘤对药物敏感，提示其在治疗抵抗性癌症患者中的潜在应用。
